Medicus Pharma advances pipeline during Q2 with key milestones
Proactive Investors
Published: Aug 13, 2026, 12:52 PM
Sentiment Analysis
Medicus Pharma (NASDAQ:MDCX) has reported second quarter financial results and regulatory and clinical progress across its SkinJect and Teverelix programs, while raising about $40 million through equity and debt financing during the first half of 2026. The company said it received FDA “Study May Proceed” authorization for its registrational SkinJect study in patients with Gorlin Syndrome. Its Teverelix program received Institutional Review Board authorization and positive FDA feedback for an optimized Phase 2 study in acute urinary retention, while the company also received UAE Department of Health authorization to begin the PRECISION-E2 Phase 2 study evaluating Teverelix in women with symptomatic endometriosis.
“The second quarter of 2026 marked a defining period for Medicus as we successfully advanced both of our lead therapeutic platforms into their next stages of clinical and regulatory development, while strengthening our balance sheet and financial flexibility,” Medicus CEO Dr. Raza Bokhari said. "We believe Medicus is well positioned with two differentiated programs advancing towards late-stage development, each addressing significant commercial opportunities through distinct regulatory pathways and multiple anticipated value-creating milestones.”
For SkinJect, Medicus reported additional pre-specified analyses from its completed Phase 2 SKNJCT-003 study, showing clinical and histological clearance rates of 64% and 55%, respectively, at the 200 microgram dose. The company said the FDA authorization allows it to init...
Source: Proactive Investors
This content is not intended as investment advice or a recommendation. Any opinions expressed are solely the personal views of each article.